These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1205 related items for PubMed ID: 29031038

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
    Tuononen K, Tynninen O, Sarhadi VK, Tyybäkinoja A, Lindlöf M, Antikainen M, Näpänkangas J, Hirvonen A, Mäenpää H, Paetau A, Knuutila S.
    Genes Chromosomes Cancer; 2012 Jan; 51(1):20-9. PubMed ID: 21922591
    [Abstract] [Full Text] [Related]

  • 7. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY, Min KW.
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [Abstract] [Full Text] [Related]

  • 8. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M.
    BMC Cancer; 2019 Oct 17; 19(1):968. PubMed ID: 31623593
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.
    Cancer Sci; 2012 Mar 17; 103(3):587-92. PubMed ID: 22136423
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J, Yang JH, Quan J, Kang X, Wang HJ, Dai PG.
    Tumour Biol; 2016 Oct 17; 37(10):13571-13579. PubMed ID: 27468718
    [Abstract] [Full Text] [Related]

  • 14. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M, German Glioma Network.
    Clin Cancer Res; 2013 Sep 15; 19(18):5146-57. PubMed ID: 23918605
    [Abstract] [Full Text] [Related]

  • 15. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W.
    Neuro Oncol; 2014 Dec 15; 16(12):1630-8. PubMed ID: 25028501
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z, Geara F, Najjar M, Comair Y, Khoueiry-Zgheib N, Khoueiry P, Mahfouz R, Boulos FI, Kamar FG, Andraos T, Saadeh F, Kreidieh F, Abboud M, Skaf G, Assi HI.
    Clin Neurol Neurosurg; 2019 Jul 15; 182():92-97. PubMed ID: 31108342
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y, Kobayashi K, Saito K, Shimizu S, Suzuki K, Sasaki N, Shiokawa Y, Nagane M.
    Jpn J Clin Oncol; 2021 Jan 01; 51(1):45-53. PubMed ID: 32888020
    [Abstract] [Full Text] [Related]

  • 19. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W, Li M, Jiang Y, Zhang C, Cai J, Wang K, Wu A.
    J Neurosurg; 2016 Jul 01; 125(1):7-16. PubMed ID: 26544773
    [Abstract] [Full Text] [Related]

  • 20. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
    Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.
    Mod Pathol; 2013 Jul 01; 26(7):922-9. PubMed ID: 23429602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.